[Anasarca, a complication of chemotherapy with gemcitabine in two patients with pancreatic cancer].
Pancreatic adenocarcinoma is the fifth most common cause of cancer-related mortality in the world. The nucleoside analogue gemcitabine is the established standard therapy for advanced disease. Rare cases of gemcitabine-associated systemic capillary leak syndrome have been reported. Here, we present two cases of capillary-leak syndrome in patients with pancreatic cancer treated with gemcitabine.
Dahan
Laetitia
L
Service d'hépatogastroentérologie et oncologie digestive; Marseille.
Ressiot
Emmanuelle
E
Cournede
Agnès
A
Ries
Pauline
P
Duluc
Muriel
M
Laquiere
Arthur
A
Laugier
René
R
Braguer
Diane
D
Seitz
Jean-François
JF
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019559:Capillary Leak Syndrome / Q000139:chemically induced*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D004487:Edema / Q000139:chemically induced*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D010534:Peritoneal Neoplasms / Q000556:secondary; D018714:Radiotherapy, Adjuvant; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors*; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D012264:Ribonucleotide Reductases; D000093542:Gemcitabine